Direxion Daily S&P Biotech Bull 3x Shares Rating $114.40 +1.29 (+1.14%) Closing price 10/23/2025 04:10 PM EasternExtended Trading$115.50 +1.10 (+0.96%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Direxion Daily S&P Biotech Bull 3x Shares Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy 2.67Holdings in LABU have an aggregate rating of Moderate Buy based on 290 analyst ratings issued in the past year covering 14 companies (12.6% of the portfolio).LABU Aggregate Price Target$114.40High Prediction$114.40Average Prediction$114.40Low Prediction$114.40Holdings in LABU have an aggregate price target of $114.40 and a range of $114.40 to $114.40 covering 14 companies (12.6% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3x Shares Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 14 LABU Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.07%CRSPCRISPR Therapeutics$67.21+1.0%2.4795 of 5 stars2.42$72.59 8.0%19Gap Up0.93%IONSIonis Pharmaceuticals$71.503.2067 of 5 stars2.80$78.50 9.8%200.91%MRNAModerna$26.25-2.2%4.2522 of 5 stars2.00$36.86 40.4%21Trending NewsAnalyst ForecastGap Down0.91%EXASExact Sciences$64.85+3.1%4.4086 of 5 stars2.92$69.90 7.8%24Analyst Forecast0.91%RVMDRevolution Medicines$53.44+0.9%4.3124 of 5 stars3.00$77.50 45.0%16Analyst Forecast0.91%INSMInsmed$160.12-0.2%3.0622 of 5 stars2.86$152.88 -4.5%21Positive NewsUpcoming Earnings0.89%UTHRUnited Therapeutics$426.21+1.1%4.7377 of 5 stars2.57$461.62 8.3%14Positive NewsUpcoming EarningsInsider Trade0.88%ABBVAbbVie$228.74+0.0%4.631 of 5 stars2.74$234.80 2.6%27Trending NewsUpcoming EarningsAnalyst Revision0.87%AMGNAmgen$292.89-1.0%4.5474 of 5 stars2.28$300.94 2.7%18Positive News0.87%NTRANatera$195.00+3.7%1.8868 of 5 stars2.80$197.59 1.3%20Trending NewsAnalyst ForecastInsider TradeShort Interest ↑0.86%RNAAvidity Biosciences$48.55+3.6%2.658 of 5 stars2.95$67.78 39.6%190.86%VRTXVertex Pharmaceuticals$422.63-0.9%4.8044 of 5 stars2.62$494.38 17.0%29Positive News0.85%BBIOBridgeBio Pharma$53.81+1.1%4.5525 of 5 stars2.88$65.25 21.3%17Analyst Forecast0.85%EXELExelixis$38.05+5.5%4.7842 of 5 stars2.64$44.53 17.0%25Trending NewsAnalyst UpgradeAnalyst Revision This page (NYSEARCA:LABU) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3x Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3x Shares With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LABU Stock Alerts